The use of docetaxel according to the Phase III CHAARTED (NCT00309985) trial suggested a survival advantage in patients with de novo high-volume metastatic castration-sensitive prostate cancer (mCSPC). However, the use of docetaxel is still under debate in regard to the timing of either metastatic onset or disease burden. Orazio Caffo, MD, Santa Chiara Hospital, Pisa, Italy, shares the first analysis from an Italian multicenter observational study (ECHOS trial) on the real-world outcomes of docetaxel in patients with mCSPC. Clinical records were reviewed of 568 patients with mCSPC with docetaxel in 34 Italian Institutions. The majority of patients (78%) were classified as having a de novo/high-volume mCSPC, the rest had relapsed/low-volume (2.5%), relapsed/high-volume (8.1%), and de novo/low-volume (11.5%). After a median follow-up of 22 months, 389 patients experienced disease progression and 227 died. The results demonstrate that docetaxel is proposed in patients not only with de novo/high volume mCSPC, but also in other patients regardless of metastases timing and disease volume. The prognosis of patients with de novo/high-volume treated with docetaxel appears to be worse than in the CHAARTED trial. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
